Literature DB >> 24256732

Drug discovery: Pocket of opportunity.

Gideon Bollag1, Chao Zhang.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24256732     DOI： 10.1038/nature12835

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  10 in total

1.  Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity.

Authors:  Till Maurer; Lindsay S Garrenton; Angela Oh; Keith Pitts; Daniel J Anderson; Nicholas J Skelton; Benjamin P Fauber; Borlan Pan; Shiva Malek; David Stokoe; Mary J C Ludlam; Krista K Bowman; Jiansheng Wu; Anthony M Giannetti; Melissa A Starovasnik; Ira Mellman; Peter K Jackson; Joachim Rudolph; Weiru Wang; Guowei Fang
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-19       Impact factor: 11.205

Review 2.  Inhibition of Ras for cancer treatment: the search continues.

Authors:  Antonio T Baines; Dapeng Xu; Channing J Der
Journal:  Future Med Chem       Date:  2011-10       Impact factor: 3.808

3.  Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors.

Authors:  Eric K Rowinsky
Journal:  J Clin Oncol       Date:  2006-06-12       Impact factor: 44.544

4.  US National Cancer Institute's new Ras project targets an old foe.

Authors:  Helen Thompson
Journal:  Nat Med       Date:  2013-08       Impact factor: 53.440

5.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

6.  Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling.

Authors:  Gunther Zimmermann; Björn Papke; Shehab Ismail; Nachiket Vartak; Anchal Chandra; Maike Hoffmann; Stephan A Hahn; Gemma Triola; Alfred Wittinghofer; Philippe I H Bastiaens; Herbert Waldmann
Journal:  Nature       Date:  2013-05-22       Impact factor: 49.962

7.  In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction.

Authors:  Fumi Shima; Yoko Yoshikawa; Min Ye; Mitsugu Araki; Shigeyuki Matsumoto; Jingling Liao; Lizhi Hu; Takeshi Sugimoto; Yuichi Ijiri; Azusa Takeda; Yuko Nishiyama; Chie Sato; Shin Muraoka; Atsuo Tamura; Tsutomu Osoda; Ken-ichiro Tsuda; Tomoya Miyakawa; Hiroaki Fukunishi; Jiro Shimada; Takashi Kumasaka; Masaki Yamamoto; Tohru Kataoka
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-29       Impact factor: 11.205

8.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

9.  K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.

Authors:  Jonathan M Ostrem; Ulf Peters; Martin L Sos; James A Wells; Kevan M Shokat
Journal:  Nature       Date:  2013-11-20       Impact factor: 49.962

10.  Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation.

Authors:  Qi Sun; Jason P Burke; Jason Phan; Michael C Burns; Edward T Olejniczak; Alex G Waterson; Taekyu Lee; Olivia W Rossanese; Stephen W Fesik
Journal:  Angew Chem Int Ed Engl       Date:  2012-05-08       Impact factor: 15.336
  10 in total
  7 in total

1.  Enhanced MET Translation and Signaling Sustains K-Ras-Driven Proliferation under Anchorage-Independent Growth Conditions.

Authors:  Saori Fujita-Sato; Jacqueline Galeas; Morgan Truitt; Cameron Pitt; Anatoly Urisman; Sourav Bandyopadhyay; Davide Ruggero; Frank McCormick
Journal:  Cancer Res       Date:  2015-05-14       Impact factor: 12.701

2.  Computational Modeling Reveals that Signaling Lipids Modulate the Orientation of K-Ras4A at the Membrane Reflecting Protein Topology.

Authors:  Zhen-Lu Li; Matthias Buck
Journal:  Structure       Date:  2017-03-09       Impact factor: 5.006

3.  AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis.

Authors:  Dae Gyu Kim; Yongseok Choi; Yuno Lee; Semi Lim; Jiwon Kong; JaeHa Song; Younah Roh; Dipesh S Harmalkar; Kwanshik Lee; Ja-Il Goo; Hye Young Cho; Ameeq Ul Mushtaq; Jihye Lee; Song Hwa Park; Doyeun Kim; Byung Soh Min; Kang Young Lee; Young Ho Jeon; Sunkyung Lee; Kyeong Lee; Sunghoon Kim
Journal:  Nat Commun       Date:  2022-05-11       Impact factor: 17.694

4.  Inhibition of RAS: proven and potential vulnerabilities.

Authors:  Mariyam Zuberi; Imran Khan; John P O'Bryan
Journal:  Biochem Soc Trans       Date:  2020-10-30       Impact factor: 5.407

5.  Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism.

Authors:  Piro Lito; Martha Solomon; Lian-Sheng Li; Rasmus Hansen; Neal Rosen
Journal:  Science       Date:  2016-01-14       Impact factor: 47.728

6.  An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer.

Authors:  Adrian Vallejo; Naiara Perurena; Elisabet Guruceaga; Pawel K Mazur; Susana Martinez-Canarias; Carolina Zandueta; Karmele Valencia; Andrea Arricibita; Dana Gwinn; Leanne C Sayles; Chen-Hua Chuang; Laura Guembe; Peter Bailey; David K Chang; Andrew Biankin; Mariano Ponz-Sarvise; Jesper B Andersen; Purvesh Khatri; Aline Bozec; E Alejandro Sweet-Cordero; Julien Sage; Fernando Lecanda; Silve Vicent
Journal:  Nat Commun       Date:  2017-02-21       Impact factor: 14.919

7.  Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma.

Authors:  Wei Yang; Lingwei Meng; Kai Chen; Chenyu Tian; Bing Peng; Lei Zhong; Chunhui Zhang; Xin Yang; Jun Zou; Shengyong Yang; Linli Li
Journal:  Cancer Sci       Date:  2019-03-06       Impact factor: 6.716
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.